尿路上皮癌BRCA1基因与蛋白表达的相关性

doi:10.6040/j.issn.1671-7554.0.2017.071

摘要/Abstract

摘要： 目的探讨尿路上皮癌乳腺癌易感基因1( BRCA1)mRNA水平与蛋白表达的相关性。方法收集50例尿路上皮癌患者标本组织进行石蜡切片3~5 μm,采用免疫组织化学法检测BRCA1基因蛋白的表达。通过提取石蜡切片组织RNA进行反转录,采用实时定量PCR法检测BRCA1基因 mRNA的表达。结果 BRCA1 mRNA低表达率64%,中表达率36%;BRCAl免疫组织化学染色阳性率为88%,阴性率为12%。采用SSPS 17.0统计学软件,经Wilcoxon两样本检验,BRCAl mRNA低表达组与中表达组的免疫组化染色程度差异有统计学意义(P<0.000 1);Spearman等级相关分析显示两者呈正相关性(r_s=0.652 9)。结论实时荧光定量PCR检测mRNA表达与免疫组化检测蛋白表达皆为评估尿路上皮癌的可选方法。

关键词: 尿路上皮癌, 乳腺癌易感基因1, 蛋白表达, mRNA表达

Abstract: Objective To investigate the correlation between protein and mRNA expressions of breast cancer susceptibility gene 1(BRCA1)in epithelial urethra cancer. Methods Urothelial carcinoma samples were collected from 50 patients, and paraffin sections 3-5 μm were prepared. The protein expression of BRCA1 was detected with immunohistochemical staining. After the RNS extracted from paraffin tissues underwent reverse transcript, the mRNA expression of BRCA1 was assessed with Real-time PCR. Results The low and medium mRNA expression rates of BRCA1 were 64% and 36%, respectively. The positive and negative rate of BRCA1 immunohistochemical staining was 88% and 12%, respectively. Wilcoxon verification showed that there was a significant difference in the degree of immunohistochemical staining between the low expression group and medium expression group(P<0.000 1). Spearman rank correlation analysis indicated a positive correlation between them(r_s=0.652 9). Conclusion The mRNA expression of BRCA1 detected with Real-time PCR and protein expression detected with immunohistochemical staining are optional methods for the assessment of epithelial urethra cancer.

Key words: Breast cancer susceptibility gene 1, Protein expression, Epithelial urethra cancer, mRNA expression

中图分类号:

R547

李雁翔,张温花,杨飞龙,方量,徐忠华. 尿路上皮癌BRCA1基因与蛋白表达的相关性[J]. 山东大学学报（医学版）, 2017, 55(5): 91-94.

LI Yanxiang, ZHANG Wenhua, YANG Feilong, FANG Liang, XU Zhonghua. The correlation between BRCA1 mRNA and protein expressions in epithelial urethra cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 91-94.

参考文献

[1] 韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95.
[2] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[3] 周利群, 李学松, 熊耕砚. 中国人群尿路上皮癌新进展[J]. 北京大学学报(医学版), 2014, 46(4): 504-506.
[4] Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier[J]. Cancer Res, 1998, 58(15): 3237-3242.
[5] Jhanwar-Uniyal M. BRCA1 in cancer cell, cycle and genomic stability[J]. Front Biosci, 2003, 8(9): 1107-1117.
[6] Seery LT, Knowlden JM, Gee JM, et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers[J]. Int J Cancer, 1999, 84(3): 258-262.
[7] Joerger M, deJong D, Burylo A, et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy[J]. Lung Cancer, 2011, 74(2): 310-317.
[8] Wang L, Wei J, Qian X, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and /or docetaxe[J]. BMC Cancer, 2008, 8(1): 197.
[9] Neveling K, Kalb R, Florl AR, et al. Disruption of the FA/BRCA pathway in bladder cancer[J]. Cytogenet Genome Res, 2007, 118(2-4): 166-176.
[10] Font A, Taron M, Gago JL, et al. BRCAl mRNA expression and outcome to neoadjuvant cisplatin-based chemothorapy in baadder cancer[J]. Ann Oncol, 2011, 22(1): 139-144.
[11] 那彦群, 孙光. 中国泌尿外科疾病诊断治疗指南[M]. 北京: 人民卫生出版社, 2011: 32.
[12] Cheung G, Sahai A, Billia M, et al. Recent advances in the diagnosis and treatment of bladder cancer[J]. BMC Med, 2013, 11: 13.
[13] Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer[J]. Lancet Oncol, 2003, 4(8): 489-497.
[14] 徐光辉, 李玉, 叶胜龙, 等. 结直肠癌组织中ERCC1和BRCA1的表达及其与铂类化疗疗效的相关性[J]. 复旦学报(医学版), 2011, 38(4): 352-323. XU Guanghui, LI Yu, YE Shenglong, et al. ERCC1 and BRCA1 expressions in the tissues of colorectal cancer and its relationship with clinical significance of platinum-based chemotherapy[J]. Fudan University Journal of Medical Sciences, 2011, 38(4): 352-323.
[15] 谷海燕, 项锋钢, 信芳杰, 等. NSCLC含铂新辅助化疗后ERCC1和BRCA1表达及与疗效关系[J].齐鲁医学杂志, 2012, 27(2): 98-100. GU Haiyan, XIANG Fenggang, XIN Fangjie, et al. Expressionsof erccland brcaland their relationship with curative effect in non-small cell lung cancer after platinum-based neoadjuvant chemo therapy[J]. Medical Journal of Qilu, 2012, 27(2): 98-100.
[16] Kennedy RD, Quinn JE, Johnston PG, et al. BRCA1: mechanisms of inactivation and implications for management of patients[J]. Lancet, 2002, 360(9338): 1007-1014.
[17] Raj GV, Karavadia S, Schlomer B, et al. Conmporary use of perioperative cisplatin-based chemotherapy in patients with muscle invasive bladder cancer[J] , Cancer, 2011, 117(2): 276-282.
[18] Fedeli U, Fedewa SA, Ward EM, et al. Treatment of muscle invasive bladder cancer evidence from the National Cancer Database, 2003 to 2007[J]. J Urol, 2011, 185(1): 72-78.
[19] Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis[J]. Cancer Res, 2003, 63(19): 6221-6228.
[20] Wang B, Matsuoka S, Ballif BA, et al. Abmxas and RAP80 form a BRCAI protein complex required for the DNA damage response[J]. Science, 2007, 316(5828): 1194-1198.
[21] Lotti LV, Ottini L, D'Amico C, et al. Subcellular localization of the BRCA1 gene product in mitotic cells[J]. Genes Chromosomes Cancer, 2002, 35(3): 193-203.
[22] Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers[J]. Nat Rev Cancer, 2004, 4(10): 814-819.
[23] Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression[J]. PLoS One, 2009, 4(5): 5133.
[24] Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors[J]. J Natl Cancer Inst, 2000, 92(7): 564-569.
[25] Taron M, Rosell R, Felip E, et al. BRCAl mRNA expression levels as an indicator of chemoresistance in lung cancer[J]. Hum Mol Genet, 2004, 13(20): 2443-2449.
[26] Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway[J]. Oncogene, 2001, 20(45): 6597-6606.
[27] Gallagher DJ,Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinumsensitivity[J]. Ann Oncol, 2011, 22(5): 1127-1132.
[28] Tassone P, Di Martino MT, Ventura M, et al. Loss of BRCAl function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo[J].Cancer Biol Ther, 2009, 8(7): 648-653.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed